Akoya Biosciences' (AKYA) Equal Weight Rating Reaffirmed at Stephens

Stephens reiterated their equal weight rating on shares of Akoya Biosciences (NASDAQ:AKYA - Free Report) in a report released on Tuesday morning, MarketBeat reports. They currently have a $1.80 price objective on the stock, down from their previous price objective of $3.50.

A number of other brokerages have also weighed in on AKYA. Canaccord Genuity Group lowered shares of Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Piper Sandler downgraded shares of Akoya Biosciences from an "overweight" rating to a "neutral" rating and set a $2.40 price target for the company. in a research note on Wednesday, March 5th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, Akoya Biosciences presently has a consensus rating of "Hold" and an average target price of $3.62.

Akoya Biosciences Trading Down 4.0 %

Shares of Akoya Biosciences stock traded down $0.06 during trading on Tuesday, hitting $1.43. The stock had a trading volume of 76,983 shares, compared to its average volume of 349,572. The stock has a market cap of $71.24 million, a PE ratio of -1.21 and a beta of 1.32. Akoya Biosciences has a 12 month low of $1.39 and a 12 month high of $4.69. The firm's fifty day simple moving average is $2.11 and its 200-day simple moving average is $2.47. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85.

Remove Ads

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). Akoya Biosciences had a negative net margin of 66.77% and a negative return on equity of 162.99%. The business had revenue of $21.34 million for the quarter, compared to the consensus estimate of $21.34 million. As a group, sell-side analysts expect that Akoya Biosciences will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Akoya Biosciences

Several large investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new position in Akoya Biosciences during the fourth quarter valued at approximately $27,000. SG Americas Securities LLC purchased a new position in shares of Akoya Biosciences in the 4th quarter valued at $28,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Akoya Biosciences in the 4th quarter valued at $31,000. Bank of America Corp DE raised its position in shares of Akoya Biosciences by 39.6% in the 4th quarter. Bank of America Corp DE now owns 29,092 shares of the company's stock worth $67,000 after acquiring an additional 8,258 shares in the last quarter. Finally, Barclays PLC lifted its stake in shares of Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company's stock worth $107,000 after purchasing an additional 30,095 shares during the last quarter. Institutional investors own 79.42% of the company's stock.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.